NewAmsterdam provides 2024-2025 update: Phase 3 data, $835M cash, EMA filing in 2H25

NewAmsterdam Pharma Co N.V.

BROADWAY Phase 3 met primary endpoint: 33% LS mean LDL-C reduction (p<0.0001); exploratory MACE reduction of 21%.
Unaudited year-end cash of $835 million; funds operations through PREVAIL CVOT readout and potential commercial launch.
Menarini to submit EMA filing for obicetrapib in 2H2025; additional Phase 3 data presentations planned throughout 2025.
VINCENT Phase 2 trial exploring obicetrapib +/- PCSK9i on Lp(a) expected to complete in 2H2025.
USPTO issued composition-of-matter patent for obicetrapib, providing IP protection in US until July 2043.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.